Authors,Author(s) ID,Title,Year,Source tittle,Cited by,DOI,Country,Document Type,City,Access Type,aggregationType,EID
Dong Z.,,Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma,2017,Clinical Cancer Research,197,10.1158/1078-0432.CCR-16-2554,China;China,Article,Guangzhou;Guangzhou,1,Journal,2-s2.0-85020853056
Lee C.K.,,Checkpoint Inhibitors in Metastatic EGFR-Mutated Non–Small Cell Lung Cancer—A Meta-Analysis,2017,Journal of Thoracic Oncology,318,10.1016/j.jtho.2016.10.007,Australia;Australia,Article,Sydney;Sydney,1,Journal,2-s2.0-85015330057
Hirsch F.R.,,PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project,2017,Journal of Thoracic Oncology,620,10.1016/j.jtho.2016.11.2228,United States;United States,Article,Aurora;Aurora,1,Journal,2-s2.0-85015345322
Rittmeyer A.,,"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial",2017,The Lancet,1773,10.1016/S0140-6736(16)32517-X,Germany,Article,Immenhausen,0,Journal,2-s2.0-85008239423
Hellmann M.D.,,"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study",2017,The Lancet Oncology,467,10.1016/S1470-2045(16)30624-6,United States,Article,New York,0,Journal,2-s2.0-85007425840
Gainor J.F.,,EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis,2016,Clinical Cancer Research,449,10.1158/1078-0432.CCR-15-3101,United States,Article,Boston,1,Journal,2-s2.0-84990938506
Goldberg S.,,"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial",2016,The Lancet Oncology,459,10.1016/S1470-2045(16)30053-5,United States,Article,New Haven,1,Journal,2-s2.0-84971619894
Schabath M.,,"Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma",2016,Oncogene,77,10.1038/onc.2015.375,United States,Article,Tampa,0,Journal,2-s2.0-84975063521
Fehrenbacher L.,,"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial",2016,The Lancet,1328,10.1016/S0140-6736(16)00587-0,United States,Article,CA,0,Journal,2-s2.0-84962038946
Passiglia F.,,PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis,2016,Oncotarget,91,10.18632/oncotarget.7582,Italy,Article,Palermo,1,Journal,2-s2.0-84964746711
Herbst R.S.,,"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial",2016,The Lancet,2845,10.1016/S0140-6736(15)01281-7,United States,Article,New Haven,0,Journal,2-s2.0-84950117835
Ji M.,,PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations,2016,Cancer Biology and Therapy,66,10.1080/15384047.2016.1156256,China;China,Article,Changzhou;Changzhou,1,Journal,2-s2.0-84962115509
Siegel R.,,"Cancer statistics, 2016",2016,CA Cancer Journal for Clinicians,18365,10.3322/caac.21332,United States,Article,Atlanta,1,Journal,2-s2.0-84954400636
Brahmer J.,,Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer,2015,New England Journal of Medicine,4379,10.1056/NEJMoa1504627,United States,Article,Baltimore,1,Journal,2-s2.0-84936791837
Gettinger S.N.,,"Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer",2015,Journal of Clinical Oncology,743,10.1200/JCO.2014.58.3708,United States,Article,New York,0,Journal,2-s2.0-84936749833
Garon E.B.,,Pembrolizumab for the treatment of non-small-cell lung cancer,2015,New England Journal of Medicine,2996,10.1056/NEJMoa1501824,United States,Article,Los Angeles,0,Journal,2-s2.0-84929481480
Rizvi N.A.,,Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer,2015,Science,3608,10.1126/science.aaa1348,United States;United States;United States,Article,New York;New York;New York,0,Journal,2-s2.0-84928761118
Skoulidis F.,,"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities",2015,Cancer Discovery,282,10.1158/2159-8290.CD-14-1236,United States,Article,Houston,1,Journal,2-s2.0-84938794719
D'Incecco A.,,PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients,2015,British Journal of Cancer,349,10.1038/bjc.2014.555,Italy,Article,Florence,1,Journal,2-s2.0-84920655625
Borghaei H.,,Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer,2015,New England Journal of Medicine,4463,10.1056/NEJMoa1507643,United States,Article,Philadelphia,1,Journal,2-s2.0-84944937210
Herbst R.,,Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients,2014,Nature,2576,10.1038/nature14011,United States,Article,New Haven,0,Journal,2-s2.0-84920956735
Azuma K.,,Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer,2014,Annals of Oncology,372,10.1093/annonc/mdu242,Japan,Article,Kurume,1,Journal,2-s2.0-84923072443
Govindan R.,,Genomic landscape of non-small cell lung cancer in smokers and never-smokers,2012,Cell,747,10.1016/j.cell.2012.08.024,United States,Article,St. Louis,1,Journal,2-s2.0-84866434919
Hanna N.,,Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy,2004,Journal of Clinical Oncology,2128,10.1200/JCO.2004.08.163,United States,Article,Indianapolis,0,Journal,2-s2.0-2442661845
Shepherd F.A.,,Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum- based chemotherapy,2000,Journal of Clinical Oncology,1946,10.1200/JCO.2000.18.10.2095,United States,Article,Cleveland,0,Journal,2-s2.0-0034069620
